Literature DB >> 4018649

What is the significance of pancreatic ductal mucinous hyperplasia?

T G Allen-Mersh.   

Abstract

The prevalence, distribution, and clinical associations of pancreatic ductal mucinous hyperplasia were studied in 102 non-malignant pancreases. Ductal mucinous hyperplasia was found in over 60% of specimens and was frequently associated with increased fibrosis--occasionally resembling pancreatitis. Significantly more ductal mucinous hyperplasia was found in pancreas from patients who were receiving corticosteroid treatment. Neither a history of hypercalcaemia in the three months before death, diabetes mellitus, alcoholism, tobacco smoking, nor the presence of gall stones was associated with an increase in ductal mucinous hyperplasia. The age of maximum prevalence, and the distribution of ductal mucinous hyperplasia in the pancreas were similar to those of pancreatic carcinoma. These similarities may be because both ductal mucinous hyperplasia and pancreatic carcinoma are proliferative responses, rather than because ductal mucinous hyperplasia is a precursor of pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018649      PMCID: PMC1432781          DOI: 10.1136/gut.26.8.825

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  A study of pancreatography.

Authors:  M BIRNSTINGL
Journal:  Br J Surg       Date:  1959-09       Impact factor: 6.939

2.  Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids.

Authors:  F A CARONE; A A LIEBOW
Journal:  N Engl J Med       Date:  1957-10-10       Impact factor: 91.245

3.  Pancreatic duct hyperplasia and cancer.

Authors:  S C SOMMERS; S A MURPHY; S WARREN
Journal:  Gastroenterology       Date:  1954-11       Impact factor: 22.682

4.  Aberrant pyloric glands in regional ileitis.

Authors:  A F LIBER
Journal:  AMA Arch Pathol       Date:  1951-02

5.  [Effect of protracted administration of corticosteroids on exocrine pancreatic secretion in man (author's transl)].

Authors:  J Bourry; H Sarles
Journal:  Gastroenterol Clin Biol       Date:  1978-02

6.  Validity of the correlation of gallstones and pancreatic pathology.

Authors:  W F Erber; E Lubowski; I S Levij; D Birnbaum
Journal:  Gut       Date:  1972-12       Impact factor: 23.059

7.  The effect of residual insulin secretion on exocrine pancreatic function in juvenile-onset diabetes mellitus.

Authors:  B M Frier; O K Faber; C Binder; H L Elliot
Journal:  Diabetologia       Date:  1978-05       Impact factor: 10.122

8.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

9.  Pathogenesis of duct hyperplasia in the pancreas.

Authors:  S Kozuka
Journal:  Digestion       Date:  1980       Impact factor: 3.216

Review 10.  Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases.

Authors:  P M Pour; S Sayed; G Sayed
Journal:  Am J Clin Pathol       Date:  1982-02       Impact factor: 2.493

View more
  4 in total

1.  [Spectrum of chronic pancreatitis. On the way to etiological classification].

Authors:  G Klöppel; B Sipos; J Lüttges
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

2.  Pancreatic ductal mucinous hyperplasia: distribution within the pancreas, and effect of variation in ampullary and pancreatic duct anatomy.

Authors:  T G Allen-Mersh
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

Review 3.  CFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis.

Authors:  Péter Hegyi; Michael Wilschanski; Shmuel Muallem; Gergely L Lukacs; Miklós Sahin-Tóth; Aliye Uc; Michael A Gray; Zoltán Rakonczay; József Maléth
Journal:  Rev Physiol Biochem Pharmacol       Date:  2016       Impact factor: 5.545

4.  Pancreatic fibrosis associated with age and ductal papillary hyperplasia.

Authors:  Sönke Detlefsen; Bence Sipos; Bernd Feyerabend; Günter Klöppel
Journal:  Virchows Arch       Date:  2005-07-14       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.